Assertio Holdings, Inc. - Common Stock (ASRT)

Competitors to Assertio Holdings, Inc. - Common Stock (ASRT)

Assertio Therapeutics, Inc. 

As a subsidiary of Assertio Holdings, Assertio Therapeutics aims to compete within the pharmaceutical landscape, particularly in pain management and neurology. Their established range of products, including both branded and generic medications, allows for a well-rounded approach to market competition in the sectors they target. Assertio Holdings is inherently leading in its own metrics but is also competing against generics and new entrants into the market.

Biohaven Pharmaceutical Holding Company Ltd. 

Biohaven focuses on neuroscience, particularly in developing treatments for disorders like migraines, which are not directly in Assertio's primary focus area. However, the broader pain management sector overlaps, creating competition. Biohaven's significant funding and rapid product pipeline development arguably position it with a competitive edge over Assertio's more established but narrower therapeutic focus.

Galena Biopharma, Inc.

Galena Biopharma focuses on developing immunotherapeutic products for cancer treatment and competes with Assertio in the oncology space. Both companies aim to innovate in the pharmaceutical sector, particularly in addressing unmet medical needs. However, Assertio's established portfolio of revenue-generating products gives it an edge, as Galena is still working to commercialize its offerings.

Horizon Therapeutics plc

Horizon Therapeutics specializes in rare disease treatments among other therapies and competes with Assertio in the autoimmune and pain management markets. Horizon's reputation for developing targeted therapies provides it a competitive edge, especially as it has more resources for R&D and marketing than Assertio, enabling robust growth and new product introductions.

Zymeworks Inc.

Zymeworks specializes in the development of multifunctional therapeutics for treating cancer, which places it in direct competition with Assertio Holdings in the oncology market segment. Zymeworks possesses proprietary technology that enables it to design optimized therapeutics, which may offer a competitive advantage over Assertio's existing product lines as it continues to innovate.